Type I interferons (IFN) are a potent antiviral cytokine group that are key regulators of the immune response against virus infection. Not only does this group activate antiviral states within target cells, it can modulate the innate immune response. In the studies presented, we investigate the effects of type I IFN on the innate immune system during a mucosal vaginal virus infection, herpes simplex virus type 2 (HSV-2), a prominent sexually transmitted infection that causes genital herpes and increases risk of human immunodeficiency virus acquisition. It is well known that type I IFN is critical for natural killer (NK) cell activation. These cells contribute to the antiviral response by suppressing virus replication and aiding in the initiation of the adaptive immune response, particularly through the release of IFN-γ. In the work presented, we demonstrate that type I IFN does not act on NK cells directly for their activation, but instead activates NK cell IFN-γ production by inducing inflammatory monocytes to release IL-18, which in turn, signals NK cells to release IFN-γ during a mucosal HSV-2 infection. Rather, direct action of type I IFN on NK cells serves to negatively regulate their IFN-γ response. We also found that type I IFN was critical for suppressing virus-induced innate immunopathology during HSV-2 infection. Overall, our studies further our understanding of type I IFN and the many roles it plays during virus infection, which has become more relevant as specific therapies altering type I IFN are being used in the clinic. Further, we provide a fundamental understanding of type I IFN and its ability to shape the innate immune response to virus infection by suppressing dysregulated and immunopathological functions while promoting beneficial innate immune responses that can help fight the infection. / Thesis / Doctor of Philosophy (PhD) / Type I interferons (IFN) are a group of proteins that are rapidly produced early during infection and is important for combatting virus infections. We show that type I IFN is not just an antiviral molecule, but can modulate the initial immune response to virus infection. As part of the initial immune response, Natural killer (NK) cells are immune cells that respond rapidly to infection and are a key element in controlling the early stages of infection. We found that type I IFN is critical for activating NK cell function by signaling through an intermediary cell, but can also suppress that same function by directly acting on NK cells. We also found that type I IFN is critical for suppressing a dysregulated immune response that causes severe virus-induced vaginal pathology. Overall, our data suggests that type I IFN is a key antiviral molecule that shapes the immune response to virus infection.

<p>Polyacryl starch microparticles have been developed as an oral vaccine adjuvant capable of inducing strong local and systemic immune responses in mice. In this thesis, the starch microparticles were studied in order to increase basic understanding of their function. In particular, the thesis addressed aspects of the uptake of the particles and their presentation to the immune system after different routes of administration, in correlation with the differentiation of the induced immune response.</p><p>When using human serum albumin as a model antigen conjugated to the microparticles, it was found that the route of administration and the use of different combinations of routes, parenteral or oral, affect the profile (Th1/Th2 balance) of the induced immune response. It was also found that oral boosters are needed for the development of a local s-IgA response. </p><p>Ligated mouse intestinal loops in combination with confocal laser-scanning microscopy demonstrated that the uptake of the particles by the intestinal mucosa takes place over the follicle-associated epithelium (FAE) that covers the Peyer’s patches. The particles are also taken up in the villus epithelium when conjugated with rCTB, a ligand to the GM1 receptor. This qualitative difference in uptake did not affect the induced immune response. Thus, the addition of rCTB to the microparticles did not improve or influence the profile of the immune response. Chronic stress, known to alter the barrier function of the FAE, increased the cellular response but did not affect the humoral immune response. </p><p>Despite positive results in rodents, the particles were not able to boost a humoral immune response in man when tested with diphtheria toxin-cross reacting material (CRM197). Possible methods of improving the adjuvant effect in man are discussed.</p>

Polyacryl starch microparticles have been developed as an oral vaccine adjuvant capable of inducing strong local and systemic immune responses in mice. In this thesis, the starch microparticles were studied in order to increase basic understanding of their function. In particular, the thesis addressed aspects of the uptake of the particles and their presentation to the immune system after different routes of administration, in correlation with the differentiation of the induced immune response. When using human serum albumin as a model antigen conjugated to the microparticles, it was found that the route of administration and the use of different combinations of routes, parenteral or oral, affect the profile (Th1/Th2 balance) of the induced immune response. It was also found that oral boosters are needed for the development of a local s-IgA response. Ligated mouse intestinal loops in combination with confocal laser-scanning microscopy demonstrated that the uptake of the particles by the intestinal mucosa takes place over the follicle-associated epithelium (FAE) that covers the Peyer’s patches. The particles are also taken up in the villus epithelium when conjugated with rCTB, a ligand to the GM1 receptor. This qualitative difference in uptake did not affect the induced immune response. Thus, the addition of rCTB to the microparticles did not improve or influence the profile of the immune response. Chronic stress, known to alter the barrier function of the FAE, increased the cellular response but did not affect the humoral immune response. Despite positive results in rodents, the particles were not able to boost a humoral immune response in man when tested with diphtheria toxin-cross reacting material (CRM197). Possible methods of improving the adjuvant effect in man are discussed.

No description available.